Nirogacestat May Offer an Additional Treatment Option for Desmoid Tumors

Commentary
Video

Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.

In an interview with CancerNetwork® during Sarcoma Awareness Month 2023, Brian Van Tine, MD, PhD, spoke about his work on the phase 3 DeFi study (NCT03785964) evaluating nirogacestat (Ogsiveo) in patients with desmoid tumors, and how this agent may expand treatment options for this population if it were to receive FDA approval.1

Van Tine, a professor of medicine in the Division of Oncology, Section of Medical Oncology at Washington University School of Medicine’s Siteman Cancer Center, also discussed how sorafenib (Nexavar) acted as a catalyst that led to the evolution of treatment for this patient population and even resulted in the publication of a National Comprehensive Cancer Network (NCCN) compendium listing for desmoid tumors.2

The FDA granted priority review to nirogacestat as a treatment for adult patients with desmoid tumors in February 2023.3

Transcript:

The treatment of desmoid [tumors] has actually been evolving rapidly since the phase 3 Alliance clinical trial [NCT02066181] that first reported the activity of sorafenib.4 And in that same study, we found out there was a 20% spontaneous regression rate of this tumor if you do nothing. Our understanding of this tumor has changed and evolved. We've done a lot of work in this area, and what's interesting is that we understand there's a β‐catenin mechanism, and nirogacestat gets into that signaling. And all of a sudden, not only do we have sorafenib as an NCCN compendium listing for the treatment of desmoid [tumors], but nirogacestat, which is hopefully coming out as an FDA-approved treatment for desmoid [tumors].

The data that came out in the [phase 3 DeFi] trial are reminiscent of that of sorafenib. The [adverse] effect profiles are different between the 2 agents, but having more than one drug for the desmoid population as this treatment paradigm evolves and we now treat these tumors more medically than surgically, having more than one option is good.

References

  1. Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388(10):898-912. doi:10.1056/NEJMoa2210140
  2. NCCN. Clinical Practice Guidelines in Oncology. Soft tissue sarcoma, version 2.2023. Accessed July 24, 2023. bit.ly/3Y58VTn
  3. SpringWorks Therapeutics announces FDA acceptance and priority review of new drug application for nirogacestat for the treatment of adults with desmoid tumors. News release. SpringWorks Therapeutics. February 27, 2023. Accessed February 27, 2023. bit.ly/3SxA1Qk
  4. Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018; 379:2417-2428. doi:10.1056/NEJMoa1805052
Recent Videos
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.
Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.
Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.
Related Content